Nalpain (Nalbuphine Hydrochloride)

Nalbuphine Hydrochloride, the active ingredient in Nalpain, is an opioid analgesic presented as a sterile injectable solution for intramuscular, intravenous, or subcutaneous use. It is employed to manage moderate to severe pain in adult patients when other analgesics are insufficient or not tolerated, and may be selected for its mixed agonist‑antagonist profile.

GNH USA supplies Nalpain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Nalpain (nalbuphine hydrochloride) is indicated for pain conditions that involve the opioid pathway.

Acute postoperative pain: provides effective analgesia for moderate to severe pain following surgical procedures. Labor pain: offers analgesic relief during childbirth while limiting respiratory depression. Cancer‑related pain: helps control moderate to severe malignant pain when other opioids are unsuitable.

Nalpain may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Nausea - Sweating - Headache - Constipation

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Anaphylactic or severe allergic reaction

When using Nalpain, clinicians should observe several precautionary measures to ensure patient safety.

Assess pain severity: confirm that opioid therapy is appropriate. Monitor respiratory function: observe for signs of depression, especially after dose adjustments. Use caution in patients with head injury or increased intracranial pressure. Avoid abrupt discontinuation: taper gradually to prevent withdrawal. Adjust dose in hepatic impairment: reduce dosage as needed. Store at ambient temperature: keep in original container, protect from moisture and light.

Nalpain can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): additive respiratory depression. - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension. - Other opioids: increased risk of profound sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise nalbuphine levels. - Antihistamines: potential for enhanced sedation. - Antihypertensive agents: possible additive hypotensive effect.